Form 4: AYTU Director Donofrio Receives 10,000 Restricted Shares

AYTU BioPharma Director John Donofrio Jr. was granted 10,000 shares of common stock, vesting in October 2026, increasing his direct beneficial ownership to 13,762 shares.

Summary

• John Donofrio Jr., a Director of AYTU BioPharma, Inc., acquired 10,000 shares of common stock.
• The acquisition occurred on October 3, 2025, and was a grant of restricted stock.
• These restricted shares will vest on October 3, 2026.
• Following this transaction, Donofrio Jr. directly beneficially owns a total of 13,762 shares of AYTU common stock.
• The transaction price for the acquired shares was $0, typical for restricted stock grants.

Sentiment

Score: 7

Explanation: The grant of restricted stock to a director is a positive signal, indicating continued alignment of interests and a commitment to the company's future. It's a standard compensation practice, not an extraordinary event, hence a moderately positive score.

Positives

• Director John Donofrio Jr. received a grant of 10,000 restricted shares, indicating continued alignment of management interests with shareholder value.
• The increase in direct beneficial ownership to 13,762 shares demonstrates a strengthened stake in the company by a key director.

Future Outlook

The filing indicates a future vesting event for the restricted stock on October 3, 2026, aligning the director's long-term incentives with the company's performance.

Industry Context

Insider equity grants are a common form of executive and director compensation in the biotechnology and pharmaceutical industry, aiming to align leadership interests with long-term shareholder value. This grant is consistent with standard practices for retaining and incentivizing key personnel in growth-oriented sectors.

Comparison to Industry Standards

• The grant of restricted stock at a $0 price is a standard practice for director compensation, similar to equity awards seen at comparable biotech firms like BioNTech or Moderna for their non-executive directors.
• The vesting period of approximately one year (October 2025 to October 2026) is within typical industry ranges for such grants, often designed to encourage long-term commitment.
• The total beneficial ownership of 13,762 shares for a director is a moderate stake, comparable to director holdings in small to mid-cap biopharma companies, reflecting a vested interest without being an overwhelmingly dominant position.

Corporate Governance

Related Party Transactions

• The grant of 10,000 restricted common shares to Director John Donofrio Jr. is a related party transaction, representing a form of director compensation.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with long-term shareholder value, as the shares vest over time.
• Management/Employees: Reflects standard compensation practices for directors, potentially boosting morale and retention.

Next Steps

• The restricted shares will vest on October 3, 2026.

Key Dates

Recommendation

This Form 4 filing reports a routine insider transaction—a restricted stock grant to a director. While it indicates continued alignment of interests, it does not present new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It's an expected part of director compensation.

Keywords

AYTU BioPharma, AYTU, Form 4, Insider Transaction, Restricted Stock, Director Compensation, Equity Grant, John Donofrio Jr.